Show simple item record

dc.contributor.authorScolnik, MPen_US
dc.contributor.authorMorilla, Ren_US
dc.contributor.authorBracco, MMDEDen_US
dc.contributor.authorCatovsky, Den_US
dc.contributor.authorMatutes, Een_US
dc.date.accessioned2018-09-17T15:18:31Z
dc.date.issued2002en_US
dc.identifier7en_US
dc.identifier.citationLeukemia Research, 2002, 26 pp. 615 - 619en_US
dc.identifier.issn0145-2126en_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/2752
dc.identifier.doi10.1016/S0145-2126(01)00182-5en_US
dc.description.abstractWe estimated by quantitative flow cytometry (FC) the expression of CD13, CD33, CD34 and CD117 antigens in cells from 64 patients with acute myeloid leukaemia (AML) and 22 normal bone marrows (BMs). The method converts fluorescence intensity into number of antigen molecules per cell, measured by antibody binding capacity (ABC). The number of molecules per cell in normal BM was 9.5±5.7 for CD13, 7±2.3 for CD33, 6±0.7 for CD34, and 6.3±1.5×103 for CD117. AML blasts expressed 11.4±12.4 molecules per cell for CD13, 9.5±9.7 for CD33, 74±2328.5 for CD34 and 12.5±33×103 for CD117. The number of CD34 and CD117 molecules were significantly higher in AML than in normals (P<0.0001 and P<0.05, respectively) while only in a few cases, CD13 and CD33 were abnormally expressed in myeloblasts. Our results indicate that quantitative analysis of CD34 and CD117 may be useful to detect minimal residual disease (MRD) and could be tested in a future to monitor therapy in AML.en_US
dc.format.extent615 - 619en_US
dc.titleCD34 and CD117 are overexpressed in AML and may be valuable to detect minimal residual diseaseen_US
dc.typeJournal Article
rioxxterms.versionofrecord10.1016/S0145-2126(01)00182-5en_US
rioxxterms.licenseref.startdate2002en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfLeukemia Researchen_US
pubs.noteskeywords: Quantitative flow cytometry, Minimal residual disease, AML, c-Kit, CD34en_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Molecular Haematology (including Cytogenetics Group and Cell Markers)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Molecular Haematology (including Cytogenetics Group and Cell Markers)
pubs.volume26en_US
pubs.embargo.termsNot knownen_US
icr.researchteamMolecular Haematology (including Cytogenetics Group and Cell Markers)en_US
dc.contributor.icrauthorCatovsky, Danielen_US
dc.contributor.icrauthorMatutes, Estellaen_US
dc.contributor.icrauthorMorilla, Ricardoen_US


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record